Mesothelioma other diagnostic studies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Mesothelioma}} | {{Mesothelioma}} | ||
{{CMG}}{{AE}}{{SR}} | |||
==Overview== | ==Overview== | ||
:* Antibodies to cytokeratin proteins are positive, differentiating these neoplasms from many sarcomas but not adenocarcinomas. | :* Antibodies to cytokeratin proteins are positive, differentiating these neoplasms from many sarcomas but not adenocarcinomas. | ||
:*The absence of staining with CEA or Leu-M1 differentiates them from adenocarcinomas. | :*The absence of staining with CEA or Leu-M1 differentiates them from adenocarcinomas. | ||
:*Recent evidence shows that Wilms’ Tumor Antigen 1 may help differentiate mesothelioma from adenocarcinoma. | :*Recent evidence shows that Wilms’ Tumor Antigen 1 may help differentiate mesothelioma from adenocarcinoma. | ||
==Other Diagnostic Studies== | |||
===Position Emission Tomography=== | |||
*Positron emission tomography is becoming useful in two clinical settings: | |||
:*Differentiating between benign and malignant asbestos-related pleural thickening | |||
:*Assessing for nodal metastases | |||
*In addition, there appears to be a correlation between the degree of [[Fludeoxyglucose F 18|FDG uptake]] and the biological aggressiveness of the tumor, which may help to guide treatment. | |||
==References== | ==References== | ||
Revision as of 01:08, 12 February 2016
|
Mesothelioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mesothelioma other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Mesothelioma other diagnostic studies |
|
Risk calculators and risk factors for Mesothelioma other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
- Antibodies to cytokeratin proteins are positive, differentiating these neoplasms from many sarcomas but not adenocarcinomas.
- The absence of staining with CEA or Leu-M1 differentiates them from adenocarcinomas.
- Recent evidence shows that Wilms’ Tumor Antigen 1 may help differentiate mesothelioma from adenocarcinoma.
Other Diagnostic Studies
Position Emission Tomography
- Positron emission tomography is becoming useful in two clinical settings:
- Differentiating between benign and malignant asbestos-related pleural thickening
- Assessing for nodal metastases
- In addition, there appears to be a correlation between the degree of FDG uptake and the biological aggressiveness of the tumor, which may help to guide treatment.